Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||RX-5902||Phase I||Actionable||In a Phase I trial, RX-5902 treatment resulted in stable disease in 43% (15/35) of patients with advanced solid tumors (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 258P; NCT02003092).||detail...|
|PubMed Id||Reference Title||Details|
|Phase 1 study of RX-5902, a novel orally bioavailable inhibitor of phosphorylated P68, which prevents b-catenin translocation in advanced solid tumors||Full reference...|